Edgewise Therapeutics Sells Sevasemten for Up to $2.65B, Pivots to Cardiovascular Focus
Event summary
- Edgewise Therapeutics sells sevasemten and muscular dystrophy business to Servier for $1.55B upfront, with up to $1.1B in milestones.
- Transaction expected to close in Q3 2026, strengthening Edgewise's balance sheet and funding cardiovascular pipeline development.
- Edgewise to focus on cardiovascular pipeline, including EDG-7500 for hypertrophic cardiomyopathy and EDG-15400 for HFpEF.
- 12-week data from CIRRUS-HCM Phase 2 trial of EDG-7500 expected in Q2 2026, with Phase 3 initiation targeted for Q4 2026.
The big picture
Edgewise Therapeutics' sale of its muscular dystrophy business to Servier marks a strategic pivot towards cardiovascular therapies, a move that aligns with industry trends favoring focused, high-impact pipelines. The $1.55B upfront payment significantly strengthens Edgewise's financial position, enabling it to pursue ambitious clinical timelines for its lead cardiovascular candidates. Servier's acquisition underscores the growing interest in precision therapeutics for rare diseases, positioning the company as a major player in neuromuscular indications.
What we're watching
- Pipeline Execution
- Whether Edgewise can successfully advance EDG-7500 and EDG-15400 through key value-inflection points.
- Regulatory Milestones
- The pace at which sevasemten achieves regulatory milestones under Servier's stewardship.
- Financial Flexibility
- How Edgewise utilizes the upfront proceeds to fully fund EDG-7500 development and expand its cardiovascular pipeline.
Related topics